Getting Wegovy in Liverpool: the clinical picture, clearly explained

What the clinical trial evidence actually says about semaglutide

The evidence base for Wegovy is well-established. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity or overweight and at least one weight-related condition over 68 weeks. Those taking 2.4 mg semaglutide weekly alongside lifestyle support lost an average of around 15% of their body weight. That figure is a population average from a controlled trial, individual results depend on adherence, diet, activity and your own physiology, and no prescription service can guarantee a particular outcome for you personally.

NICE reviewed this evidence and recommended semaglutide (Wegovy) for NHS use under specific conditions: it should be used for a maximum of two years, within a specialist weight management service offering multidisciplinary support, and only if you have at least one weight-related comorbidity and a BMI of 35 or above (with thresholds typically 2.5 kg/m² lower for some ethnic backgrounds under UK guidance). If less than 5% weight loss is achieved after six months on the maintenance dose, NICE recommends reviewing whether to continue. Full details are in NICE technology appraisal TA875.

One development worth knowing: the MHRA approved a higher 7.2 mg semaglutide maintenance dose in early 2026, and a dedicated single-dose 7.2 mg pen followed in April 2026. Trial data for the higher dose reported around 20.7% average weight loss over 72 weeks, approaching results seen with tirzepatide at its highest dose. Whether a specific dose or pen format is available to you is something a prescriber confirms at consultation, not something any service can guarantee in advance. You can read more about the full Wegovy treatment range on our Wegovy overview page.

NHS Wegovy access in Liverpool versus going private, an honest comparison

Liverpool sits within NHS Cheshire and Merseyside ICB. Wegovy on the NHS is dispensed through commissioned specialist weight management services (typically tier 3 services) and demand has consistently outpaced capacity since TA875 was published in 2023. That is not a local failure; it reflects a national pattern. If you meet the NICE criteria (broadly: BMI 35-plus, at least one qualifying comorbidity, referred by your GP), you may be eligible for an NHS referral, but a prescriber cannot give you a reliable timeline for when a funded course would actually start.

Private prescription is the path many Liverpool residents take instead. It does not require a GP referral and has no waiting list, but the clinical assessment is just as real. A GPhC-registered prescriber reviews your health history, your BMI, your medications and your medical background before any treatment is approved. The GPhC pharmacy register is the right place to check whether any online pharmacy offering Wegovy is properly registered. Semaglutide is a prescription-only medicine; any seller offering it without a clinical assessment is operating outside the law, and the MHRA has warned publicly about counterfeit weight-loss pens circulating online.

If you're considering private treatment, the guide to where Wegovy can be bought safely in the UK covers what to look for and what to avoid. At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber, your answers land on a clinician's desk, not in an automated filter. Orders placed before 12 pm on a working day are dispatched the same day once approved, arriving by DPD the next working day in plain packaging. Worth checking whether that lines up with your schedule, a Monday order before noon, for instance, means your pen is with you by Tuesday.

Safety, side effects and situations where Wegovy is not suitable

Wegovy's side-effect profile is led by gastrointestinal symptoms: nausea, loose stools, constipation, indigestion, and occasionally vomiting, particularly during the early weeks of treatment or after a dose increase. These usually ease as your body adjusts, though they don't disappear entirely for everyone. The NHS semaglutide medicines page describes them clearly and is a useful first read alongside the patient information leaflet.

Pancreatitis is a less common but more serious concern. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines specifically highlighting acute pancreatitis: severe stomach pain that radiates towards the back, with or without vomiting, needs urgent medical attention rather than a wait-and-see approach. Report any suspected side effects, including from a course that has already ended, at yellowcard.mhra.gov.uk.

There are situations where Wegovy is straightforwardly not suitable. Pregnancy, breastfeeding, and active attempts to conceive all sit in that category, the medicine is not recommended, and if there is any chance of pregnancy a prescriber will ask you to stop before trying. Women using oral contraceptives alongside semaglutide should discuss their contraception with their prescriber; for those switching to tirzepatide, there is a specific guidance note about oral contraceptive absorption in the first weeks of treatment, which our detailed page on Wegovy and pregnancy explains alongside the broader fertility picture. Anyone with a history of medullary thyroid carcinoma, MEN2, or a personal history of pancreatitis will also need a careful prescriber discussion before starting.

Semaglutide also has effects beyond weight loss that some people ask about. If you have questions about how the medicine interacts with blood sugar levels or liver health, our pages on blood sugar effects in people without diabetes and on Wegovy and liver health, including a closer look at what the evidence says about Wegovy's effect on the liver specifically, go into the evidence in more detail. Personal suitability, in every case, is a decision for your prescriber, not a webpage.